To assess whether hypertensive disorders of pregnancy (HDP) vary by underlying causes of infertility.
Background/Objectives: Endometriosis is frequently associated with infertility and may affect several aspects of reproductive competence. However, whether women with endometriosis exhibit different preimplantation genetic testing for aneuploidy (PGT-A) outcomes compared …
Delayed parenthood is a defining feature of contemporary reproductive medicine, fundamentally reshaping reproductive planning and increasing reliance on medically assisted reproduction (MAR). For women of advanced reproductive age (ARA), this …
Environmental microbiological monitoring is mandatory in IVF laboratories; however, procedure-specific risk assessment across the entire medically assisted reproduction workflow remains limited. This multicenter study, named "SMILE" (Study of Environmental Microbiological …
Background and Objectives: Endometriosis is a chronic inflammatory disease associated with impaired fertility, but the extent to which its systemic inflammatory profile differs from that observed in infertile women without …
Endometriosis affects approximately 10% of women of reproductive age and is associated with infertility in up to half of those diagnosed. Despite decades of research, the molecular basis of its …
Endometriosis is an estrogen-dependent inflammatory disorder associated with pelvic pain, infertility, repeated treatment, and impaired quality of life. Thyroid dysfunction and thyroid autoimmunity are also common in reproductive-aged women and …
Endometriosis is frequently associated with infertility and postoperative recurrence, and fertility-sparing surgery may be considered when symptoms, endometriomas, adhesions, or deep infiltrating disease are unlikely to be adequately managed with …
Endometriosis affects a substantial proportion of women of reproductive age and is a common, often under-recognised contributor to subfertility. Its effects on fertility are multifactorial, and both the disease and …
It is critical that women undertaking medically assisted reproductive (MAR) treatment and their clinicians know whether the treatments are associated with an increased risk of hormone-related cancers.